Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Guidance on the use of MRI for treatment planning in radiotherapy clinical trials.

Johnstone RI, Guerrero-Urbano T, Michaelidou A, Greener T, Miles E, Eaton D, Thomas C.

Br J Radiol. 2020 Jan;93(1105):20190161. doi: 10.1259/bjr.20190161. Epub 2019 Dec 5.

PMID:
31724876
2.

Radiotherapy Trial Set-up in the UK: Identifying Inefficiencies and Potential Solutions.

Hanna CR, Lynskey DM, Wadsley J, Appleyard SE, Anwar S, Miles E, Gower J, Hall E, Coles CE, Hanna GG.

Clin Oncol (R Coll Radiol). 2019 Nov 1. pii: S0936-6555(19)30451-0. doi: 10.1016/j.clon.2019.10.004. [Epub ahead of print]

3.

Provision of Organ at Risk Contouring Guidance in UK Radiotherapy Clinical Trials.

Yang H, Mir R, Díez P, Tsang Y, Conibear J, Simões R, Cox S, Webster A, Nabi Z, Eaton D, Naismith O, Whilde N, Miles E.

Clin Oncol (R Coll Radiol). 2020 Feb;32(2):e60-e66. doi: 10.1016/j.clon.2019.09.054. Epub 2019 Oct 11.

PMID:
31607614
4.

Inter-Observer Variability in Target Volume Delineations of Benign and Metastatic Brain Tumours for Stereotactic Radiosurgery: Results of a National Quality Assurance Programme.

Growcott S, Dembrey T, Patel R, Eaton D, Cameron A.

Clin Oncol (R Coll Radiol). 2020 Jan;32(1):13-25. doi: 10.1016/j.clon.2019.06.015. Epub 2019 Jul 10.

PMID:
31301960
5.

Target Volume Delineation Training for Clinical Oncology Trainees: The Role of ARENA and COPP.

Evans E, Radhakrishna G, Gilson D, Hoskin P, Miles E, Yuille F, Dickson J, Gwynne S.

Clin Oncol (R Coll Radiol). 2019 Jun;31(6):341-343. doi: 10.1016/j.clon.2019.03.003. Epub 2019 Apr 6. No abstract available.

PMID:
30962050
6.

Driving developments in UK oesophageal radiotherapy through the SCOPE trials.

Gwynne S, Higgins E, Poon King A, Radhakrishna G, Wills L, Mukherjee S, Hawkins M, Jones G, Staffurth J, Crosby T.

Radiat Oncol. 2019 Feb 4;14(1):26. doi: 10.1186/s13014-019-1225-0.

7.

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).

Strauss VY, Shaw R, Virdee PS, Hurt CN, Ward E, Tranter B, Patel N, Bridgewater J, Parsons P, Radhakrishna G, O'Neill E, Sebag-Montefiore D, Hawkins M, Corrie PG, Maughan T, Mukherjee S.

BMC Cancer. 2019 Feb 4;19(1):121. doi: 10.1186/s12885-019-5307-z.

8.

Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.

Hatton MQF, Lawless CA, Faivre-Finn C, Landau D, Lester JF, Fenwick J, Simões R, McCartney E, Boyd KA, Haswell T, Shaw A, Paul J.

BMJ Open. 2019 Jan 29;9(1):e019903. doi: 10.1136/bmjopen-2017-019903.

9.

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group.

Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15.

10.

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS.

Gollins S, West N, Sebag-Montefiore D, Susnerwala S, Falk S, Brown N, Saunders M, Quirke P, Ray R, Parsons P, Griffiths G, Maughan T, Adams R, Hurt C.

Br J Cancer. 2018 Sep;119(6):697-706. doi: 10.1038/s41416-018-0209-4. Epub 2018 Aug 17.

11.

Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.

Conibear J, Chia B, Ngai Y, Bates AT, Counsell N, Patel R, Eaton D, Faivre-Finn C, Fenwick J, Forster M, Hanna GG, Harden S, Mayles P, Moinuddin S, Landau D.

BMJ Open. 2018 Apr 17;8(4):e020690. doi: 10.1136/bmjopen-2017-020690. Erratum in: BMJ Open. 2019 May 9;9(5):e020690corr1.

12.

Unintended doses in radiotherapy-over, under and outside?

Eaton DJ, Byrne JP, Cosgrove VP, Thomas SJ.

Br J Radiol. 2018 Apr;91(1084):20170863. doi: 10.1259/bjr.20170863. Epub 2018 Jan 18.

13.

Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.

Wills L, Maggs R, Lewis G, Jones G, Nixon L, Staffurth J, Crosby T; SCOPE 1 trial management group and collaborators.

Radiat Oncol. 2017 Nov 15;12(1):179. doi: 10.1186/s13014-017-0916-7.

14.

A virtual dosimetry audit - Towards transferability of gamma index analysis between clinical trial QA groups.

Hussein M, Clementel E, Eaton DJ, Greer PB, Haworth A, Ishikura S, Kry SF, Lehmann J, Lye J, Monti AF, Nakamura M, Hurkmans C, Clark CH; Global Quality Assurance of Radiation Therapy Clinical Trial Harmonisation Group.

Radiother Oncol. 2017 Dec;125(3):398-404. doi: 10.1016/j.radonc.2017.10.012.

PMID:
29100698
15.

Dependence of volume calculation and margin growth accuracy on treatment planning systems for stereotactic radiosurgery.

Eaton DJ, Alty K.

Br J Radiol. 2017 Dec;90(1080):20170633. doi: 10.1259/bjr.20170633. Epub 2017 Oct 12.

16.

A multicentre audit of HDR/PDR brachytherapy absolute dosimetry in association with the INTERLACE trial (NCT015662405).

Díez P, Aird EGA, Sander T, Gouldstone CA, Sharpe PHG, Lee CD, Lowe G, Thomas RAS, Simnor T, Bownes P, Bidmead M, Gandon L, Eaton D, Palmer AL.

Phys Med Biol. 2017 Nov 9;62(23):8832-8849. doi: 10.1088/1361-6560/aa91a9.

PMID:
28984277
17.

The role of dosimetry audit in lung SBRT multi-centre clinical trials.

Clark CH, Hurkmans CW, Kry SF; Global Quality Assurance of Radiation Therapy Clinical Trials Harmonisation Group.

Phys Med. 2017 Dec;44:171-176. doi: 10.1016/j.ejmp.2017.04.003. Epub 2017 Apr 5. Review.

PMID:
28391958
18.

Four-dimensional Computed Tomography Contouring Variability in Stereotactic Body Radiotherapy of Non-resectable Biliary Tract Cancer.

Robinson M, Eaton D, Holyoake D, Hawkins M.

Clin Oncol (R Coll Radiol). 2017 Jul;29(7):e137. doi: 10.1016/j.clon.2017.02.016. Epub 2017 Mar 18. No abstract available.

PMID:
28325599
19.

An external dosimetry audit programme to credential static and rotational IMRT delivery for clinical trials quality assurance.

Eaton DJ, Tyler J, Backshall A, Bernstein D, Carver A, Gasnier A, Henderson J, Lee J, Patel R, Tsang Y, Yang H, Zotova R, Wells E.

Phys Med. 2017 Mar;35:25-30. doi: 10.1016/j.ejmp.2017.02.012. Epub 2017 Feb 22.

PMID:
28236559
20.

Evaluating Target Volume Delineation in the Era of Precision Radiotherapy: FRCR, Revalidation and Beyond.

Gwynne S, Gilson D, Dickson J, McAleer S, Radhakrishna G.

Clin Oncol (R Coll Radiol). 2017 Jul;29(7):436-438. doi: 10.1016/j.clon.2017.01.045. Epub 2017 Feb 17. No abstract available.

PMID:
28222956

Supplemental Content

Loading ...
Support Center